BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16923613)

  • 1. CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
    Oyekunle A; Koehl U; Schieder H; Ayuk F; Renges H; Fehse N; Zabelina T; Fehse B; Klingebiel T; Sputtek A; Zander A; Kröger N
    Cytotherapy; 2006; 8(4):375-80. PubMed ID: 16923613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
    Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
    Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
    Roberts MM; Dyson P; Rawling C; Thorp D; Rawling T; White D; Horvath N; Bardy P; Hui CH; Dart GW; To LB; Hughes TP
    Cytotherapy; 2003; 5(6):534-41. PubMed ID: 14660049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
    Larocca A; Piaggio G; Podestà M; Pitto A; Bruno B; Di Grazia C; Gualandi F; Occhini D; Raiola AM; Dominietto A; Bregante S; Lamparelli T; Tedone E; Oneto R; Frassoni F; Van Lint MT; Pogliani E; Bacigalupo A
    Haematologica; 2006 Jul; 91(7):935-40. PubMed ID: 16818281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation of selected peripheral CD34+ cells with controlled CD3+ cells add-back in high-risk patients.
    Markiewicz M; Hołowiecki J; Wojnar J; Krawczyk-Kuliś M; Jagoda K; Giebel S; Kruzel T
    Transplant Proc; 2004 Dec; 36(10):3194-9. PubMed ID: 15686727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors.
    Matsuda Y; Hara J; Osugi Y; Fujisaki H; Takai K; Ohta H; Nakanishi K; Tokimasa S; Miyoshi H; Tanaka-Taya K; Yamanishi K; Okada S
    Bone Marrow Transplant; 1998 Feb; 21(4):355-60. PubMed ID: 9509968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful engraftment of allogeneic CD34-enriched marrow cell transplantation from HLA-mismatched parental donors.
    Yabe H; Yabe M; Hattori K; Hinohara T; Morimoto T; Nakamura Y; Noma M; Takei M; Kobayashi N; Tsuji K; Kato S
    Bone Marrow Transplant; 1996 Jun; 17(6):985-91. PubMed ID: 8807104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
    Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
    Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrelated peripheral blood stem cell transplantation with 'megadoses' of purified CD34+ cells in three children with refractory severe aplastic anemia.
    Schwinger W; Urban C; Lackner H; Kerbl R; Benesch M; Dornbusch HJ; Sovinz P; Schauenstein K; Schumm M; Handgretinger R
    Bone Marrow Transplant; 2000 Mar; 25(5):513-7. PubMed ID: 10713628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.
    Baron F; Schaaf-Lafontaine N; Humblet-Baron S; Meuris N; Castermans E; Baudoux E; Frère P; Bours V; Fillet G; Beguin Y
    Transplantation; 2003 Dec; 76(12):1705-13. PubMed ID: 14688520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
    Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
    Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells.
    Cornetta K; Gharpure V; Mills B; Hromas R; Abonour R; Broun ER; Traycoff CM; Hanna M; Wyman N; Danielson C; Gonin R; Kunkel LK; Oldham F; Srour EF
    Bone Marrow Transplant; 1998 Jan; 21(1):65-71. PubMed ID: 9486497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
    Watanabe T; Kawano Y; Watanabe A; Takaue Y
    Haematologica; 1999 Feb; 84(2):167-76. PubMed ID: 10091416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian multicenter pilot trial of haploidentical donor transplantation.
    Walker I; Shehata N; Cantin G; Couture F; Dhédin N; Barty R; Foley R; Sutherland RD; Sigouin C; Schultz KR; Mitchell D;
    Blood Cells Mol Dis; 2004; 33(3):222-6. PubMed ID: 15528135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.